13F Holdings
中文EN

PMHS Polomar Health Services, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1265521 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11,701.9%
TTM net income YoY-303.9%
TTM EPS YoY-300.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin49.1%
Operating margin-221.0%
Net margin-224.6%
FCF margin—
EBITDA margin-14.8%

Returns

ROE-469.6%
ROA-193.3%
ROIC (approx.)-392.6%
Asset turnover0.86x

Leverage & solvency

Liabilities / assets325.5%
Debt / equity—
Current ratio0.24x
Interest coverage-61.19x

Cash quality & payout

Operating cash flow / net income-0.04x
Accruals ratio-200.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$648,231$58,824$41,844$34,526
Cost of revenue$188,132$27,921$4,294—
Gross profit$460,099$30,903$37,550$34,526
SG&A expense$10.94M$1.28M$450,450$215,979
Operating income-$10.55M-$1.30M-$440,832-$181,453
Interest expense$150,841$41,837$495—
Net income-$10.70M-$1.34M-$587,997-$181,124
EBITDA-$776,936-$1.04M-$434,999—
EPS (basic)-0.39-0.05-0.020.00
EPS (diluted)-0.39-0.05-0.020.00
Weighted avg. shares (diluted)27.76M27.66M26.12M—
Balance sheet
Cash & equivalents$132,150$6,191$8,808$225,619
Receivables———$30,000
Inventory$93,636$68,777$3,459—
Current assets$322,727$76,813$12,267$261,484
PP&E, net$43,452$81,405——
Total assets$390,043$9.95M$107,099$261,484
Current liabilities$1.61M$1.34M$102,455$74,715
Short-term debt——$32,484—
Total liabilities$1.61M$1.35M$151,635$74,715
Shareholders' equity-$1.97M$8.60M-$44,536$186,769
Shares outstanding28.02M27.66M27.66M107.58M
Cash flow statement
Operating cash flow-$395,995-$1.02M-$534,307-$40,934
Capital expenditure—$90,893——
Free cash flow—-$1.11M——
Investing cash flow—-$90,893——
Financing cash flow$521,954$1.11M$317,496$266,553
Depreciation & amortization$9.77M$263,280$5,833—
Stock-based compensation$129,645——$173,995

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.